Lilly furthers case for Omvoh after approval

Eli Lilly (NYSE: LLY) has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure.

Omvoh, which is seen as a potential growth driver by the US pharma major, was approved for the treatment of Crohn's disease last month, having earlier won authorization in October 2023 as a first-in-class treatment for moderately to severely active ulcerative colitis in adults.

Now Lilly is seeking to gain market share in the Crohn’s disease indication - a competitive field where competitors include Johnson & Johnson's (NYSE: JNJ) Stelara (ustekinumab) - and has presented new data in this setting at the Crohn's and Colitis Congress 2025 in San Francisco.